Medical Device Network on MSN1h
Foresight announces trial launch for cHL treatment with ctDNA-based MRD test
Foresight Diagnostics and the University of Washington School of Medicine and Fred Hutch Cancer Center have announced the ...
CURE8d
Minimal Residual Disease Testing’s Variability Across Cancer Types
Dr. Christopher R. Flowers explains that MRD testing varies by cancer type, with results impacting recurrence risk and ...
BizWest2d
Foresight Diagnostics expands Allogene partnership
Foresight Diagnostics Inc., a Boulder-based cancer diagnostics company that specialized in the development of ultra-sensitive minimal residual disease, or MRD, detection, recently expanded its ...
Oncology Nurse Advisor3d
Sustained MRD Negativity Observed With Cilta-Cel
Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...
Business Wire3d
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cance ...
Medindia6d
Non-Invasive ctDNA Testing for Early Detection of Multiple Myeloma
Discover how ctDNA revolutionizes multiple myeloma monitoring, tracking disease progression, and improving personalized ...
EurekAlert!10d
New technique to measure circulating tumor DNA in metastatic cancer may improve disease progression surveillance and patient outcomes
In metastatic cancer surveillance, monitoring the actual concentrations of circulating tumor DNA (ctDNA) may be critical.
Healio13d
Hematology/Oncology News
In this video, Arvind Dasari, MD, MS, discussed data from multiple ASCO Gastrointestinal Cancers Symposium presentations highlighting the use of ctDNA as a minimal residual disease in colorectal ...